Publications

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open 2025;11:e005371 doi: 10.1136/rmdopen-2024-005371

Burmester GR,

Mysler E,

Taylor P,

Hall S,

Wick-Urban B,

Garrison A,

Gao T,

Fish I,

Strengholt S,

Fleischmann R

Burmester et al. provide insights into the benefit–risk profiles of UPA and adalimumab in patients with varying cardiovascular (CV) risks, suggesting that UPA may offer efficacy advantages over adalimumab irrespective of baseline CV risk, with generally similar rates of AEs. To better understand the benefits and risks of RA treatments in patients with different background CV risk, Burmester et al. assessed the short-term and long-term benefit–risk profiles of UPA and adalimumab in patients enrolled in SELECT-COMPARE.

Keywords:

• Cardiovascular,
• Efficacy,
• MTX,
• Safety,
• Upadacitinib

免疫介在性炎症疾患におけるヤヌスキナーゼ阻害薬の相違

Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448

Taylor PC,

Choy E,

Baraliakos X,

Szekanecz Z,

Xavier RM,

Isaacs JD,

Strengholt S,

Parmentier JM,

Lippe R,

Tanaka Y

JAKis differ in structure, which affects their inhibitory concentration for different JAKs.

This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.

Keywords:

• JAK,
• Basic Science,
• MOA

心血管疾患リスクのある患者にこえるウパダシチニブの安全性: 関節リウマチに対するSELECTフェーズ3開発プログラムの統合事後解析

Ann Rheum Dis. 2023 doi: 10.1136/ard-2023-223916

Fleischmann R,

Curtis JR,

Charles-Schoeman C,

Mysler E,

Yamaoka K,

Richez C,

Palac H,

Dilley D,

Liu J,

Strengholt S,

Burmester G

Pots hoc analysis of safety data in patients with RA at increased risk of CV events from the upadacitinib SELECT phase III RA clinical programme helps to contextualise the overall risk profile of upadacitinib.

Keywords:

• JAK,
• Upadacitinib,
• Phase 3,
• Safety,
• Cardiovascular

関節リウマチにおけるJAK阻害薬による日和見感染症: システマティックレビュー

Semin Arthritis Rheum. 2023;58:152120

Winthrop K,

Isaacs J,

Calabrese L,

Mittal D,

Desai S,

Barry J,

Strengholt S,

Galloway J

Structured literature review shows a varied incidence of opportunistic infections (OIs) among RA patients exposed to JAK inhibitors.

Keywords:

• JAK,
• Safety,
• Infections,
• Review

トファシチニブ治療中関節リウマチ患者の間質性肺疾患発生率

J Clin Rheumatol. 2021;27(8):e482–e490

Citera G,

Mysler E,

Madariaga H,

Cardiel MH,

Castañeda O,

Fischer A,

Richette P,

Chartrand S,

Park JK,

Strengholt S,

Rivas JL,

Thorat AV,

Girard T,

Kwok K,

Wang L,

Ponce de Leon D

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients....

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Lung / ILD

長期試験においてtofacitinibで治療された関節リウマチ患者の画像的進行評価

Rheumatology (Oxford). 2021;60(4):1708-1716.

van der Heijde D,

Landewé RBM,

Wollenhaupt J,

Strengholt S,

Terry K,

Kwok K,

Wang L,

Cohen S.

Long-term evaluation of tofacitinib has found limited progression of structural damage in patients with RA treated with tofacitinib for up to 5 years. Similar results were also observed for patients receiving tofacitinib monotherapy or combination therapy for up to 3 years.It is well known that inflammation in RA leads to structural damage over time, and therapies such as DMARDS have the ability to reduce inflammation whilst inhibiting the progression of structural damage. In this study, van der...

Keywords:

• JAK,
• Tofacitinib,
• LTE,
• Radiographic

トファシチニブで治療された関節リウマチ患者における 間質性肺炎の頻度

Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.

Citera G,

Mysler E,

Madariaga H,

Cardiel M H,

Castaneda O,

Fischer A,

Richette P,

Chartrand S,

Park J K,

Strengholt S,

Rivas J L,

Thorat A V,

Girard T,

Kwok K,

Wang L

This study highlights the importance of accounting for known risk factors of RA-ILD in clinical practice. Interstitial lung disease (ILD) is an extra-articular manifestation of RA. The post-hoc investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. This post-hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 21 Phase 1-4, and 2 long-term ex...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Lung / ILD

関節リウマチ治療における，Tofacitinib の 9.5年間の有効性 と安全性: グローバル，オープンラベル，長期延長試験の最 終結果

Arthritis Res Ther. 2019 Apr 5;21(1):89.

Wollenhaupt J,

Lee EB,

Curtis JR,

Silverfield J,

Terry K,

Soma K,

Mojcik C,

DeMasi R,

Strengholt S,

Kwok K,

Lazariciu I,

Wang L,

Cohen S

TOF 5 mg and 10mg BID demonstrated a consistent safety profile and sustained efficacy for up to 9.5 years in this open-label LTE ORAL Sequel study.TOF 5 mg and 10 mg BID demonstrated consistent safety (as monotherapy and combination therapy) and efficacy within this open-label LTE study of RA patients. As RA requires long-term treatment, it’s important to assess the long-term efficacy and safety of RA therapies to understand the potential lifelong impact on patient health and quality of life. Th...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Efficacy,
• LTE

関節リウマチ患者におけるトファシチニブのリンパ球に対する短期、中期、長期的影響

Arthritis Rheumatol 2018 DOI: 10. 1002/art.40780

van Vollenhoven R,

Lee EB,

Strengholt S,

Mojcik C,

Valdez H,

Krishnaswami S,

Biswas P,

Lazariciu I,

Hazra A,

Clark JD,

Hodge J,

Wang L,

Choy E

Tofacitinib (TOF) treatment is associated with short-term transient increases in absolute lymphocyte counts (ALC), followed by a gradual decline to reach steady state by ~48 months. Changes in both ALC and lymphocyte subset counts (LSC) were reversible upon TOF discontinuation. Low ALC but not LSC were associated with an increased risk of serious infective episodes (SIEs) and herpes zoster (HZ). This data supported the treatment recommendations on ALC counts for starting and continuing therapy w...

Keywords:

• JAK,
• Tofacitinib,
• MOA